SARcode develops Sunesis' LFA-1 IP for inflammation
In order to concentrate more on oncology, Sunesis (uses its Tethering discovery engine to identify small molecules) has licensed biopharma SARcode exclusive worldwide rights to patents and know-how covering inhibitors of leukocyte integrin function-associated antigen-1 (LFA-1).
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.